Jazeta Novum

Sitagliptin phosphate monohydrate, the active ingredient in Jazeta Novum, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is prescribed to improve glycemic control in adults with type 2 diabetes mellitus. It works by enhancing the body’s own incretin hormones, thereby increasing insulin secretion and reducing glucagon release in a glucose‑dependent manner.

GNH USA supplies Jazeta Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for cross‑border medication delivery.

Jazeta Novum (sitagliptin) is used in the management of type 2 diabetes mellitus, a chronic disorder of glucose metabolism. - Type 2 diabetes mellitus: improves glycemic control when added to diet and exercise. - Inadequate control on metformin alone: provides additional HbA1c reduction as part of combination therapy. - Combination with sulfonylureas: enhances overall glucose lowering while allowing dose adjustments of co‑medications.

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient cranial pain. - Upper respiratory tract infection: symptoms such as cough and congestion. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain and elevated enzymes. - Severe allergic reactions: including rash, angioedema, or anaphylaxis. - Joint pain (arthralgia): persistent musculoskeletal discomfort. - Bullous pemphigoid: rare blistering skin disorder.

When prescribing Jazeta Novum, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: dose may need adjustment in patients with reduced kidney function. - Hepatic impairment: use with caution in moderate liver disease. - Hypoglycemia risk: monitor blood glucose when combined with insulin or sulfonylureas. - History of pancreatitis: avoid or use only if benefits outweigh risks. - Cardiovascular disease: assess patient’s cardiac status as sitagliptin has a neutral CV profile. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): may raise sitagliptin plasma concentrations. - Rifampin: may reduce sitagliptin exposure, decreasing effectiveness.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium levels. - Diuretics: watch for changes in blood pressure and electrolytes. - Warfarin: periodic INR testing recommended.